醒脑静注射液与疏血通注射液对急性脑梗死的疗效与经济学比较  

Comparison of Therapeutic Effects and Economics Between Xingnaojing Injection and Shuxuetong Injection in the Treatment of Acute Cerebral Infarction

作　　者：邹红 姜衍[1] 赵辰阳[1] ZOU Hong;JIANG Yan;ZHAO Chenyang(Department of Pharmacy,the Second Hospital of Dalian Medical University,Dalian Liaoning 116023,China)

机构地区：[1]大连医科大学附属第二医院药学部,辽宁大连116023

出　　处：《中国卫生标准管理》2025年第4期144-148,共5页China Health Standard Management

基　　金：大连市医学科学研究计划项目(20Z12008)。

摘　　要：目的 探讨醒脑静注射液与疏血通注射液治疗急性脑梗死的临床疗效并进行成本-效果分析。方法 采用回顾性调查方法,将2020年10月—2022年12月大连医科大学附属第二医院收治73例急性脑梗死患者,剔除不符合要求病例后,最终纳入60例,根据治疗药物分为醒脑静组与疏血通组,各30例。根据治疗前后美国国立卫生研究所脑卒中量表评分(National Institute of Health stroke scale,NIHSS)以及日常生活活动评价Barthel指数的改变评估2组治疗药物的有效性,运用药物经济学成本-效果分析方法评估2组药物的经济性。结果 治疗后醒脑静组的临床总有效率为83.33%,疏血通组为76.67%,差异无统计学意义(P> 0.05)。治疗前,醒脑静组与疏血通组的Barthel指数分别为(55.50±23.76)分和(57.67±24.59)分,治疗后Barthel指数分别为(69.33±29.32)分和(66.67±23.46)分。2组治疗前后Barthel指数均有提高(P <0.001),2组治疗后Barthel指数变化比较,差异无统计学意义(P=0.206)。醒脑静组的药费花费(5 117.53±1499.58)元、检查费(2 442.20±1 631.89)元、住院费(343.91±64.41)元、总成本(7 903.63±2 463.49)元,疏血通组的药费花费(3 295.27±1 238.56)元、检查费(2 282.99±1 125.80)元、住院费(309.64±60.06)元、总成本(5 887.90±1 928.66)元,差异有统计学意义(P <0.05)。成本(Cost,C)以总住院费进行统计,效果(Effect,E)用NIHSS评分的减少表示,2组成本-效果比依次为2 136.12以及2 238.40。结论 醒脑静注射液与疏血通注射液均可改善急性脑梗死患者的神经功能,提高患者日常生活能力,醒脑静组每多获得一个单位效果的花费少于疏血通组102.28元,说明醒脑静注射液更为经济、合理。Objective To explore the clinical efficacy of Xingnaojing and Shuxuetong Injection in the treatment of acute cerebral infarction and conduct a cost-effectiveness analysis.Methods A retrospective survey was conducted on 73 patients with acute cerebral infarction admitted to the Second Hospital of Dalian Medical University from October 2020 to December 2022.After excluding cases that did not meet the requirements,60 cases were finally included and divided into the Xingnaojing group and the Shuxuetong group based on the treatment drugs,with 30 cases in each group.The effectiveness of the two treatment drugs was evaluated based on changes in the National Institute of Health stroke scale(NIHSS)and the Barthel Index of Activities of Daily Living before and after treatment.The cost-effectiveness analysis method of pharmacoeconomics was used to evaluate the economic viability of the two groups of drugs.Results After treatment,the total effective rate of Xingnaojing group was 83.33%,and that of Shuxuetong group was 76.67%,the difference was not statistically significant(P>0.05).Before treatment,the Barthel index of Xingnaojing group and Shuxuetong group were(55.50±23.76)points and(57.67±24.59)points respectively,and after treatment,the Barthel index were(69.33±29.32)points and(66.67±23.46)points respectively.The Barthel index of the two groups were improved before and after treatment(P<0.001),and there was no significant difference between the two groups after treatment(P=0.206).The drug cost of Xingnaojing group was(5117.53±1499.58)yuan,the examination cost was(2442.20±1631.89)yuan,the hospitalization cost was(343.91±64.41)yuan,the total cost was(7903.63±2463.49)yuan,and the drug cost of Shuxuetong group was(3295.27±1238.56)yuan,the examination cost was(2282.99±1125.80)yuan,and the hospitalization cost was(309.64±60.06)yuan,the differences were statistically significant(P<0.05).The cost(c)was calculated by the total hospitalization expenses,and the effect(E)was expressed by the reduction of NIHSS score.The cos

关 键 词：醒脑静注射液 疏血通注射液 急性脑梗死 成本-效果分析 药物经济学 美国国立卫生研究院卒中量表评分 

分 类 号：R956[医药卫生—药学]